• 2006

Company Description

Tioma Therapeutics is a venture-stage biopharmaceutical company

Formerly Known as Vasculox. Tioma is an immuno-oncology company developing anti-CD47 antibodies for the treatment of solid and hematologic cancers. Our functionally diverse antibodies represent a new class of checkpoint inhibitors that harness both the adaptive and innate immune responses.